Scientific Knowledge Exchange on immunotherapy in lung cancer
In this Scientific Knowledge Exchange Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, and OA Dr. Georg Pall, Special Hospital in Wangen, discuss about immunotherapy in lung cancer.
Video Contents00:40 Keynote 042 Pembrolizumab as Monotherapy in first line 03:14 Kombination therapies in squamous NSCLC, Keynote 407+ IMpower 131 05:38 PDL-1 as Biomarker 05:50 Low expression of PD-L1, Checkmate-227 09:43 TMB as new biomarker 12:03 liquid biopsy, blood-based tumor mutational burden 13:20 combination therapy and toxicity 16:37 Take home messages from Asco 2018
Source: ASCO 2018
The following abstracts are discussed in this SKE:
Jotte RM et al, IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
Lopes G et al: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
Paz-Ares LG et al: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
Borghaei H et al: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.
Socinski MA et al: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
More from this topic:
Immuno-Oncology - ASCO 2018
Additive atezolizumab to chemotherapy delays progression in advanced squamous cell carcinoma of the lung
07. 06. 2018